Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 48

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 48
---
/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
|                                                                              |     | Six Months Ended |          |         |     |      |          |         |
|                                                                              |     |         June 30, |          |         |     |      |          |         |
|                                                                              |     |             2025 |          |         |     | 2024 |          |         |
| Warrants granted                                                             |     |                  |          | 530,330 |     |      |          | 345,079 |
| Weighted average exercise price per warrant granted (DKK)                    |     |                  | 1,604.81 |         |     |      | 2,006.50 |         |
| Weighted average Black-Scholes fair value per warrant granted (DKK)          |     |                  |   500.33 |         |     |      |   650.72 |         |
| Warrants exercised                                                           |     |                  |          |  43,921 |     |      |          |  62,374 |
| Weighted average exercise price on date of grant per warrant exercised (DKK) |     |                  | 1,057.95 |         |     |      | 1,208.46 |         |
| % change in share capital - warrants exercised                               |     |                  |     0.07 |       % |     |      |     0.09 |       % |

Refer to Note 4.6 in the Annual Report for details on the warrant program.

Share-Based Compensation Expense

Share-based compensation expenses related to Genmab’s RSU and warrant programs for the first six months of 2025 were $ 58million compared to $ 51million for the first six months of 2024.

Share Repurchases

At Genmab’s Annual General Meeting on March 12, 2025, the Board of Directors was authorized to allow Genmab to acquire treasury shares with a total nominal value of up to 10% of the share capital in the period until and including March 11, 2030. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on Nasdaq Copenhagen A/S at the time of the acquisition. Such shares may only be acquired to the extent that the Company’s total holding of treasury shares does not at any time exceed a nominal